Visipaque safer than Hexabrix for angiography:
This article was originally published in Clinica
Executive Summary
A large multi-centre US study has shown that Nycomed Amersham's non-ionic contrast agent Visipaque (iodixanol) is safer than its ionic rival, Mallinckrodt's Hexabrix (ioxaglate). In the COURT trial, 856 patients with high-risk cardiac conditions were given angiography with one or other of the agents. The Visipaque group experienced 32% fewer total clinical adverse events and 45% fewer major in-hospital adverse events, according to the study in the May 9 issue of Circulation.